CAJ | 학술논문

目的：探讨化疗联合CIK免疫疗法对晚期消化道肿瘤的效果。方法采用化疗(方案以奥沙利铂、氟尿嘧啶、卡培他滨为主)联合CIK免疫疗法治疗2005年10月-2010年1月成都军区昆明总医院收治的晚期消化道恶性肿瘤86例(观察组),将同期仅接受化疗的63例晚期消化道肿瘤设为对照组,分别于完成第2、4个疗程后2周检测两组相关免疫指标( CD56+、CD3+、CD3+CD56+、CD3+CD8+T细胞),完成第2个疗程后观察两组临床症状(体重减轻、消化道出血、恶心、呕吐)改善情况和总生存期,同时对比疗效。结果完成第2、4个疗程后观察组免疫指标均高于对照组(P<0．05,P<0．01)。完成第2个疗程后观察组体重减轻、消化道出血、恶心和呕吐症状均明显缓解(P<0．05,P<0．01)。两组近期疗效差异无统计学意义(P>0．05)。患者均获随访,随访时间0.5~5年,观察组中位生存期28个月,对照组中位生存期9个月,log-rank检验两条生存曲线差异有统计学意义(χ2=4.851,P=0.028)。结论化疗联合CIK免疫疗法治疗晚期消化道肿瘤,能够提高患者的免疫功能、减轻临床症状、延长生存期。
목적：탐토화료연합CIK면역요법대만기소화도종류적효과。방법채용화료(방안이오사리박、불뇨밀정、잡배타빈위주)연합CIK면역요법치료2005년10월-2010년1월성도군구곤명총의원수치적만기소화도악성종류86례(관찰조),장동기부접수화료적63례만기소화도종류설위대조조,분별우완성제2、4개료정후2주검측량조상관면역지표( CD56+、CD3+、CD3+CD56+、CD3+CD8+T세포),완성제2개료정후관찰량조림상증상(체중감경、소화도출혈、악심、구토)개선정황화총생존기,동시대비료효。결과완성제2、4개료정후관찰조면역지표균고우대조조(P<0．05,P<0．01)。완성제2개료정후관찰조체중감경、소화도출혈、악심화구토증상균명현완해(P<0．05,P<0．01)。량조근기료효차이무통계학의의(P>0．05)。환자균획수방,수방시간0.5~5년,관찰조중위생존기28개월,대조조중위생존기9개월,log-rank검험량조생존곡선차이유통계학의의(χ2=4.851,P=0.028)。결론화료연합CIK면역요법치료만기소화도종류,능구제고환자적면역공능、감경림상증상、연장생존기。
Objective To explore the effect of chemotherapy combined with CIK cells immunotherapy in treat-ment of advanced digestive malignant tumor. Methods A total of 86 patients with advanced gastrointestinal cancer ( ob-servation group) were treated with chemotherapy ( main components of Oxaliplatin, Fluorouracil, Capecitabine) com-bined with CIK immunotherapy during October 2005 and January 2010 in Kunming General Hospital, and 63 patients with advanced gastrointestinal tumors ( control group) received only chemotherapy at the same period. The related immune pa-rameters ( CD56 +, CD3 +, CD3 +CD56 +, CD3 +CD8 + T cells) of the two groups were detected two weeks after 2 nd and 4th courses of treatment were finished respectively, and improvements of clinical symptoms (weight loss, gastrointestinal bleeding, nausea and vomiting) and total life span were observed, and clinical effect was synchronously compared after 2nd course of treatment was completed in the two groups. Results After 2nd and 4th course of treatment was completed, the immune parameters in observation group were higher than those in control group (P<0. 05, P<0. 01). After 2nd course of treatment was completed, weight loss, gastrointestinal bleeding, nausea and vomiting were significantly allevia-ted in observation group (P<0. 05, P<0. 01), and the difference in recent curative effect was not statistically signifi-cant (P>0. 05), and the difference in recent curative effect was not statistically significant (P>0. 05) . All patients were followed up for 0. 5 - 5 years, the median life span in observation group was 28 months;median life span in control group was 9 months, and the difference in survival curves by log-rank test was statistically significant (χ2 =4. 851, P=0. 028). Conclusion Chemotherapy combined with CIK cells immunotherapy in treatment of advanced digestive malig-nant tumor may improve immune function, relieve clinical symptoms and prolong life span.